Haemonetics Corporation (HAE)
| Market Cap | 2.56B -15.5% |
| Revenue (ttm) | 1.33B -2.0% |
| Net Income | 97.31M -42.0% |
| EPS | 2.05 -38.1% |
| Shares Out | 46.47M |
| PE Ratio | 26.89 |
| Forward PE | 10.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,122,257 |
| Open | 53.66 |
| Previous Close | 54.37 |
| Day's Range | 51.00 - 56.11 |
| 52-Week Range | 47.32 - 87.32 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 81.67 (+48.17%) |
| Earnings Date | May 7, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.... [Read more]
Financial Performance
In fiscal year 2026, Haemonetics's revenue was $1.33 billion, a decrease of -1.97% compared to the previous year's $1.36 billion. Earnings were $97.31 million, a decrease of -41.97%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $81.67, which is an increase of 48.17% from the latest price.
News
Haemonetics price target lowered to $67 from $72 at Baird
Baird analyst David Rescott lowered the firm’s price target on Haemonetics (HAE) to $67 from $72 and keeps an Outperform rating on the shares. The firm updated its model following
Haemonetics price target lowered to $62 from $74 at JPMorgan
JPMorgan lowered the firm’s price target on Haemonetics (HAE) to $62 from $74 and keeps a Neutral rating on the shares.
Haemonetics Earnings Call Transcript: Q4 2026
Q4 and full-year results showed strong organic growth, margin expansion, and robust free cash flow, driven by Plasma and TEG platforms. Fiscal 2027 guidance projects continued revenue and margin growth, with innovation and portfolio transformation supporting future performance.
Haemonetics reports Q4 adjusted EPS $1.29, consensus $1.27
Reports Q4 revenue $346.35M, consensus $336.86M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma...
Haemonetics sees FY27 adjusted EPS up 4%-7%
Sees FY27 revenue up 4%-7%. Sees FY27 free cash flow conversion 80%.
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal...
Haemonetics to Present at Bank of America 2026 Healthcare Conference
BOSTON, May 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Bank of America 2026 He...
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today a...
Haemonetics price target lowered to $70 from $80 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on Haemonetics (HAE) to $70 from $80 and keeps an Outperform rating on the shares. The firm lowered estimates and price
Haemonetics price target lowered to $84 from $88 at BTIG
BTIG lowered the firm’s price target on Haemonetics (HAE) to $84 from $88 and keeps a Buy rating on the shares as part of a broader research name on Medical
Haemonetics price target lowered to $64 from $70 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics (HAE) to $64 from $70 and keeps a Neutral rating on the shares. The firm adjusted targets in the
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May...
Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system
Haemonetics (HAE) announced U.S. FDA approval to expand the labeling for the VASCADE MVP XL venous vascular closure system to include procedures using 10-14F inner diameter and up to 17F
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology ...
Haemonetics price target lowered to $70 from $75 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics (HAE) to $70 from $75 and keeps a Neutral rating on the shares. The firm adjusted targets in the
Haemonetics Transcript: 47th Annual Raymond James Institutional Investor Conference
The conference highlighted record plasma business growth, successful innovation cycles, and robust financial performance, with strong share gains and new product launches like Persona PLUS and PerQseal Elite. The company is focused on sustainable growth, operational improvements, and disciplined capital deployment.
Haemonetics receives FDA clearance for NexSys PCS Plasma Collection System
Haemonetics (HAE) announced U.S. FDA 510(k) clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology. Persona PLUS represents the next generation of Haemonetics’ proprietary ...
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today an...
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th An...
Haemonetics price target lowered to $81 from $99 at Baird
Baird lowered the firm’s price target on Haemonetics (HAE) to $81 from $99 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where
Haemonetics price target lowered to $80 from $90 at Mizuho
Mizuho lowered the firm’s price target on Haemonetics (HAE) to $80 from $90 and keeps an Outperform rating on the shares.
Haemonetics price target raised to $94 from $93 at Barrington
Barrington raised the firm’s price target on Haemonetics (HAE) to $94 from $93 and keeps an Outperform rating on the shares following what the firm calls a “mixed bag quarter.”
Haemonetics price target lowered to $75 from $88 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics (HAE) to $75 from $88 and keeps a Neutral rating on the shares.
Haemonetics Earnings Call Transcript: Q3 2026
Strong Q3 results led to raised full-year guidance for revenue, earnings, and cash flow. Plasma and blood management technologies drove growth, while interventional technologies faced headwinds but are expected to recover in FY27. Margin expansion and robust cash flow support ongoing investments.
Haemonetics reports Q3 adjusted EPS $1.31, consensus $1.25
Reports Q3 revenue $338.97M, consensus $332.72M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Third quarter revenue growth, margin expansion, and cash flow reflect the underlying strength of our core...